Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rapid Micro Biosystems ( (RPID) ) has shared an update.
On May 18, 2026, Rapid Micro Biosystems entered into an underwriting agreement with TD Securities (USA) LLC and Lake Street Capital Markets LLC for an underwritten offering of 3,581,000 shares of Class A common stock and associated Series A and Series B warrants, plus up to 1,463,000 pre-funded warrants issued in lieu of shares to certain investors. The securities, priced at a combined $1.955 per share and $1.945 per pre-funded unit, are expected to raise approximately $8.9 million in net proceeds, which the company plans to use for working capital and general corporate purposes, with the offering expected to close on May 20, 2026.
The company structured the warrants with staggered exercise prices and terms, including ownership caps, participation rights in future offerings for Series B warrant holders and protections around fundamental transactions, which may influence future dilution and investor participation dynamics. Also on May 18, 2026, Rapid Micro Biosystems agreed to a concurrent registered direct offering to certain directors and officers for 71,607 shares and matching warrants, expected to generate about $140,000 in gross proceeds and close around May 20, 2026, further bolstering liquidity while aligning insider stakeholders with the new capital raise.
The most recent analyst rating on (RPID) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.
Spark’s Take on RPID Stock
According to Spark, TipRanks’ AI Analyst, RPID is a Neutral.
The score is held down primarily by weak financial performance: large ongoing losses, heavy cash burn, and higher balance-sheet leverage. The earnings call adds some support via reaffirmed guidance, improving recurring revenue mix, and an outlined path to better margins, but execution/liquidity risks remain meaningful. Technically, the stock is still below key moving averages, and valuation is hard to assess due to negative earnings and no indicated dividend yield.
To see Spark’s full report on RPID stock, click here.
More about Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. operates in the life sciences and pharmaceutical testing sector, providing automated microbiology quality control systems to biopharma and related industries. The company’s products are aimed at improving the speed, accuracy and efficiency of microbial detection in drug manufacturing and other regulated environments, positioning it within the specialized market for rapid microbiological testing solutions.
Average Trading Volume: 196,564
Technical Sentiment Signal: Sell
Current Market Cap: $94.74M
For detailed information about RPID stock, go to TipRanks’ Stock Analysis page.